Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

RBC Emerging Markets Equity

RBC Emerging Markets Equity Fund F

DFA Emerging Markets Core Equity I

LUX IM ESG Global Emerging Equities HX

Dimensional World ex US Core Eq 2 ETF

Robeco QI EM Active Equities I €

Vanguard Total Intl Stock Index Inv

Fisher All Foreign Equity Small Cap

Fidelity SAI Global ex U.S. Low Vol Idx

Goldman Sachs Emrgng Mrkt Eqt Insg C1

Goldman Sachs Em Mkts Eq Insghts Intl

Dimensional EM LrgCap Core Eq ZUSDInsAcc

SPDR® Portfolio Emerging Markets ETF

Avantis Emerging Markets Equity ETF

SEI Emerging Markets Equity F (SIT)

Robeco QI Emerging Cnsrv Eqs I €

Vanguard Emerging Mkts Stock Idx Inv

Dimensional Emerging Core Equity Mkt ETF

Dimensional Emerging Markets Cr Eq 2 ETF

Vanguard Global Minimum Volatility Admr

Morgan Stanley - Brokerage Accounts

Robeco Institutional Asset Management BV

Goldman Sachs Group Inc

JPMorgan Chase & Co

Fisher Asset Management, LLC

GQG Partners LLC

BNP Paribas Arbitrage, SA

HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND

Jane Street Group LLC

Man Group PLC

Wellington Management Company LLP

Lazard Asset Management LLC

Royal Bank of Canada

Renaissance Technologies Corp

BlackRock Inc

Aikya Investment Management Ltd

Dimensional Fund Advisors, Inc.

Vanguard Group Inc

State Street Corp

Bank of America Corp

Dr. Reddy’s Laboratories Ltd ADR

Mr. Gunupati Venkateswara Prasad B.E.

Co-Chairman, MD & Member of Management Council

Mr. Kallam Satish Reddy B.Tech., M.S.

Chairman of the Board & Member of the Management Council

Mr. Erez  Israeli M.B.A.

CEO & Member of the Management Council

Mr. Mannam  Venkatanarasimham

CFO & Member of the Management Council

Mr. Krishna K. Venkatesh B.Pharma M.S.

Global Head of Quality and Pharmacovigilance & Member of the Management Council

Mr. Deepak  Sapra M.B.A.

CEO of API & Services & Member of Management Council

Mr. Venkata Ramana Motupalli M.B.A.

CEO of Branded Markets - India & Emerging Countries and Member of Management Council

Ms. Archana  Bhaskar B.Sc., M.B.A.

EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council

Mr. Sanjay  Sharma B.Tech.

Executive VP, Global Head of Global Manufacturing & Member of Management Council

Mr. Patrick  Aghanian B.A., M.B.A.

CEO of European Generics & Member of Management Council

RDY's next earnings is on January 28, 2025 (Before Market Open)

RDY's latest dividend is 0.47615 USD on July 30, 2024

Dr. Reddy’s Laboratories Ltd ADR (RDY) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Dr. Reddy’s Laboratories Ltd ADR (RDY) Earnings Report Date and History | NYSE

RDY's next earnings is on January 28, 2025 (Before Market Open)

When is the earnings report for RDY?

RDY Earnings History

RDY's latest dividend is 0.47615 USD on July 30, 2024

RDY Stock Discussion Forum and Message Board

News for NYSE: RDY